Video Upload Options

References

1. Aoki Y, Niihori T, Kawame H, Kurosawa K, Ohashi H, Tanaka Y, Filocamo M, Kato K, Suzuki Y, Kure S, Matsubara Y. Germline mutations in HRAS proto-oncogene causeCostello syndrome. Nat Genet. 2005 Oct;37(10):1038-40.
2. Colicelli J. Human RAS superfamily proteins and related GTPases. Sci STKE.2004 Sep 7;2004(250):RE13. Review.
3. Estep AL, Tidyman WE, Teitell MA, Cotter PD, Rauen KA. HRAS mutations inCostello syndrome: detection of constitutional activating mutations in codon 12and 13 and loss of wild-type allele in malignancy. Am J Med Genet A. 2006 Jan1;140(1):8-16.
4. Giehl K. Oncogenic Ras in tumour progression and metastasis. Biol Chem. 2005Mar;386(3):193-205. Review.
5. Gripp KW, Innes AM, Axelrad ME, Gillan TL, Parboosingh JS, Davies C, LeonardNJ, Lapointe M, Doyle D, Catalano S, Nicholson L, Stabley DL, Sol-Church K.Costello syndrome associated with novel germline HRAS mutations: an attenuatedphenotype? Am J Med Genet A. 2008 Mar 15;146A(6):683-90. doi:10.1002/ajmg.a.32227.
6. Gripp KW, Lin AE, Stabley DL, Nicholson L, Scott CI Jr, Doyle D, Aoki Y,Matsubara Y, Zackai EH, Lapunzina P, Gonzalez-Meneses A, Holbrook J, Agresta CA, Gonzalez IL, Sol-Church K. HRAS mutation analysis in Costello syndrome: genotype and phenotype correlation. Am J Med Genet A. 2006 Jan 1;140(1):1-7.
7. Gripp KW, Stabley DL, Nicholson L, Hoffman JD, Sol-Church K. Somatic mosaicismfor an HRAS mutation causes Costello syndrome. Am J Med Genet A. 2006 Oct15;140(20):2163-9.
8. Groesser L, Herschberger E, Ruetten A, Ruivenkamp C, Lopriore E, Zutt M,Langmann T, Singer S, Klingseisen L, Schneider-Brachert W, Toll A, Real FX,Landthaler M, Hafner C. Postzygotic HRAS and KRAS mutations cause nevus sebaceousand Schimmelpenning syndrome. Nat Genet. 2012 Jun 10;44(7):783-7. doi:10.1038/ng.2316.
9. Hafner C, Toll A, Gantner S, Mauerer A, Lurkin I, Acquadro F, Fernández-CasadoA, Zwarthoff EC, Dietmaier W, Baselga E, Parera E, Vicente A, Casanova A,Cigudosa J, Mentzel T, Pujol RM, Landthaler M, Real FX. Keratinocytic epidermalnevi are associated with mosaic RAS mutations. J Med Genet. 2012Apr;49(4):249-53. doi: 10.1136/jmedgenet-2011-100637.
10. Kerr B, Delrue MA, Sigaudy S, Perveen R, Marche M, Burgelin I, Stef M, Tang B,Eden OB, O'Sullivan J, De Sandre-Giovannoli A, Reardon W, Brewer C, Bennett C,Quarell O, M'Cann E, Donnai D, Stewart F, Hennekam R, Cavé H, Verloes A, PhilipN, Lacombe D, Levy N, Arveiler B, Black G. Genotype-phenotype correlation inCostello syndrome: HRAS mutation analysis in 43 cases. J Med Genet. 2006May;43(5):401-5.
11. Levinsohn JL, Tian LC, Boyden LM, McNiff JM, Narayan D, Loring ES, Yun D,Sugarman JL, Overton JD, Mane SM, Lifton RP, Paller AS, Wagner AM, Antaya RJ,Choate KA. Whole-exome sequencing reveals somatic mutations in HRAS and KRAS,which cause nevus sebaceus. J Invest Dermatol. 2013 Mar;133(3):827-830. doi:10.1038/jid.2012.379.
12. Oxford G, Theodorescu D. The role of Ras superfamily proteins in bladdercancer progression. J Urol. 2003 Nov;170(5):1987-93. Review.
13. Rauen KA. HRAS and the Costello syndrome. Clin Genet. 2007 Feb;71(2):101-8.Review.
14. Sol-Church K, Stabley DL, Nicholson L, Gonzalez IL, Gripp KW. Paternal bias inparental origin of HRAS mutations in Costello syndrome. Hum Mutat. 2006Aug;27(8):736-41.
15. Wolff EM, Liang G, Jones PA. Mechanisms of Disease: genetic and epigeneticalterations that drive bladder cancer. Nat Clin Pract Urol. 2005Oct;2(10):502-10. Review.